Published in Blood on April 17, 2009
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
IL-35-mediated induction of a potent regulatory T cell population. Nat Immunol (2010) 3.43
CARs on track in the clinic. Mol Ther (2011) 2.86
Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 2.84
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia (2010) 2.22
Gene-engineered T cells for cancer therapy. Nat Rev Cancer (2013) 2.07
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother (2010) 1.81
Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev (2014) 1.81
Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res (2011) 1.53
Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov (2013) 1.53
IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. J Clin Invest (2011) 1.46
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. PLoS One (2016) 1.44
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?". Hum Gene Ther (2009) 1.44
Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med (2012) 1.40
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506). Blood (2009) 1.39
Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother (2010) 1.38
The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer. Clin Cancer Res (2012) 1.37
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol (2010) 1.30
Immunotherapy of human cancers using gene modified T lymphocytes. Curr Gene Ther (2009) 1.29
Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther (2011) 1.27
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. Cancer Discov (2015) 1.18
Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. J Natl Cancer Inst (2016) 1.11
Novel immunotherapies in lymphoid malignancies. Nat Rev Clin Oncol (2015) 1.09
Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res (2014) 1.08
T cells redirected against CD70 for the immunotherapy of CD70-positive malignancies. Blood (2011) 1.07
Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells. Mol Ther (2014) 1.05
Positron emission tomography scanning: a new paradigm for the management of Hodgkin's lymphoma. Haematologica (2010) 1.03
Tumor evasion from T cell surveillance. J Biomed Biotechnol (2011) 1.01
Chemokines: can effector cells be redirected to the site of the tumor? Cancer J (2010) 0.98
Ex vivo gene transfer for improved adoptive immunotherapy of cancer. Hum Mol Genet (2011) 0.97
The immunogenicity of virus-derived 2A sequences in immunocompetent individuals. Gene Ther (2013) 0.96
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy. Clin Cancer Res (2016) 0.95
Chemokines in cancer development and progression and their potential as targeting molecules for cancer treatment. Mediators Inflamm (2014) 0.94
Role of the chemokine receptors CCR1, CCR2 and CCR4 in the pathogenesis of experimental dengue infection in mice. PLoS One (2010) 0.94
Dengue virus infection: current concepts in immune mechanisms and lessons from murine models. Immunology (2014) 0.92
Synthetic control of mammalian-cell motility by engineering chemotaxis to an orthogonal bioinert chemical signal. Proc Natl Acad Sci U S A (2014) 0.92
CD28z CARs and armored CARs. Cancer J (2014) 0.89
Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One (2013) 0.89
T-Cell Traffic Jam in Hodgkin's Lymphoma: Pathogenetic and Therapeutic Implications. Adv Hematol (2010) 0.88
Genetic modification of human T lymphocytes for the treatment of hematologic malignancies. Haematologica (2012) 0.88
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor. Sci Rep (2014) 0.88
Genetically modified T cells for the treatment of malignant disease. Transfus Med Hemother (2013) 0.87
Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer. BioDrugs (2015) 0.86
Optimization manufacture of virus- and tumor-specific T cells. Stem Cells Int (2011) 0.86
Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther (2009) 0.85
The Principles of Engineering Immune Cells to Treat Cancer. Cell (2017) 0.85
Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. Mol Ther (2016) 0.85
Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells. ISRN Oncol (2012) 0.84
Harnessing the immune system to improve cancer therapy. Ann Transl Med (2016) 0.83
Genetically engineered T cells for the treatment of cancer. J Intern Med (2013) 0.83
"Model t" cells: a time-tested vehicle for gene therapy. Front Immunol (2013) 0.82
Customized targeted therapy in Hodgkin lymphoma: hype or hope? Hematol Oncol Clin North Am (2014) 0.82
Adoptive T-Cell Immunotherapy. Curr Top Microbiol Immunol (2015) 0.81
CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics (2016) 0.81
CCL17 and CCL22/CCR4 signaling is a strong candidate for novel targeted therapy against nasal natural killer/T-cell lymphoma. Cancer Immunol Immunother (2015) 0.81
Immunological deregulation in classic hodgkin lymphoma. Mediterr J Hematol Infect Dis (2014) 0.81
Chimeric antigen receptor-redirected T cells return to the bench. Semin Immunol (2016) 0.81
Changes in chemokine receptor expression of regulatory T cells after ex vivo culture. J Immunother (2012) 0.80
Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery. Int J Cancer (2013) 0.80
An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites. Oncotarget (2015) 0.80
Cellular immunotherapy for malignant gliomas. Expert Opin Biol Ther (2016) 0.79
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity. Front Biosci (Schol Ed) (2012) 0.79
Developing strategies in the immunotherapy of leukemias. Cancer Control (2013) 0.79
CAR T-cell therapy of solid tumors. Immunol Cell Biol (2016) 0.78
Engineered T cells for cancer treatment. Cytotherapy (2013) 0.78
Immunotherapy in pediatric malignancies: current status and future perspectives. Future Oncol (2014) 0.78
Therapeutic targeting of regulatory T cells enhances tumor-specific CD8+ T cell responses in Epstein-Barr virus associated nasopharyngeal carcinoma. Virology (2013) 0.78
New Strategies for the Treatment of Solid Tumors with CAR-T Cells. Int J Biol Sci (2016) 0.77
Advances in T-cell therapy for ALL. Best Pract Res Clin Haematol (2014) 0.77
Adoptive T-cell therapy for Leukemia. Mol Cell Ther (2014) 0.77
Redirecting the immune response: role of adoptive T cell therapy. Hum Gene Ther (2010) 0.77
Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Biomark Med (2013) 0.76
Chimeric antigen receptor-modified T cells strike back. Int Immunol (2016) 0.76
Tumor-infiltrating HLA-matched CD4(+) T cells retargeted against Hodgkin and Reed-Sternberg cells. Oncoimmunology (2016) 0.76
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects. J Immunol Res (2016) 0.76
Designing T cells for cancer immunotherapy. Discov Med (2010) 0.76
Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies. Blood (2016) 0.76
WHO classification of myeloid neoplasms and leukemia. Blood (2010) 0.76
Chemokine receptors as therapeutic tools in Hodgkin lymphoma: CCR4 and beyond. Blood (2010) 0.76
Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology. Pediatr Blood Cancer (2015) 0.75
Novel therapies for Hodgkin Lymphoma. Ther Adv Hematol (2010) 0.75
From monoclonal antibodies to chimeric antigen receptors for the treatment of human malignancies. Semin Oncol (2014) 0.75
C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer. Oncoimmunology (2015) 0.75
Systematic evaluation of immune regulation and modulation. J Immunother Cancer (2017) 0.75
A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) (2016) 0.75
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond. Trends Mol Med (2017) 0.75
Nuclear Phosphoproteomic Screen Uncovers ACLY as Mediator of IL-2-induced Proliferation of CD4+ T lymphocytes. Mol Cell Proteomics (2016) 0.75
Chimeric antigen receptor T cells therapy for tumor immunotherapy. Biosci Rep (2017) 0.75
Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents. Int J Mol Sci (2015) 0.75
Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer (2017) 0.75
Transgelin-2 in B-Cells Controls T-Cell Activation by Stabilizing T Cell - B Cell Conjugates. PLoS One (2016) 0.75
Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma. J Immunother Cancer (2017) 0.75
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. Cancer Discov (2017) 0.75
Development of CAR T cells designed to improve antitumor efficacy and safety. Pharmacol Ther (2017) 0.75
Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities. Annu Rev Immunol (2017) 0.75
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med (2001) 5.56
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor. Nat Biotechnol (2002) 5.49
Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol (2008) 4.17
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Chemokines and the tissue-specific migration of lymphocytes. Immunity (2002) 3.58
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med (2001) 3.51
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Selective up-regulation of chemokine receptors CCR4 and CCR8 upon activation of polarized human type 2 Th cells. J Immunol (1998) 2.84
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
CD30 (Ki-1) molecule: a new cytokine receptor of the tumor necrosis factor receptor superfamily as a tool for diagnosis and immunotherapy. Blood (1995) 2.67
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood (2003) 2.47
In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood (2004) 2.28
Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease. Int J Cancer (1990) 2.28
Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood (2000) 2.15
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood (2007) 2.11
Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther (2002) 1.96
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood (2002) 1.89
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood (1998) 1.86
High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol (1999) 1.78
Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood (2004) 1.75
Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res (2006) 1.66
4-1BB is superior to CD28 costimulation for generating CD8+ cytotoxic lymphocytes for adoptive immunotherapy. J Immunol (2007) 1.57
Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood (2005) 1.36
Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Res (2005) 1.32
Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. Br J Haematol (2008) 1.22
Common and differential chemokine expression patterns in rs cells of NLP, EBV positive and negative classical Hodgkin lymphomas. Int J Cancer (2002) 1.09
An anti-CD30 chimeric receptor that mediates CD3-zeta-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res (1998) 1.02
Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function. Cancer Res (2007) 0.96
Hodgkin's lymphoma cells are efficiently engrafted and tumor marker CD30 is expressed with constitutive nuclear factor-kappaB activity in unconditioned NOD/SCID/gammac(null) mice. Cancer Sci (2005) 0.86
Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders. Br J Dermatol (2006) 0.85
Evolutionary and biomedical insights from the rhesus macaque genome. Science (2007) 16.21
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med (2008) 11.49
A catalog of reference genomes from the human microbiome. Science (2010) 8.10
The genome of the model beetle and pest Tribolium castaneum. Nature (2008) 6.50
The genome of the sea urchin Strongylocentrotus purpuratus. Science (2006) 6.41
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest (2011) 6.38
Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med (2011) 6.14
Functional and evolutionary insights from the genomes of three parasitoid Nasonia species. Science (2010) 5.56
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood (2009) 4.98
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med (2006) 4.42
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes. Blood (2004) 4.01
Repeated polyploidization of Gossypium genomes and the evolution of spinnable cotton fibres. Nature (2012) 4.00
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer. Blood (2007) 3.94
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood (2011) 3.82
Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Oncol (2013) 3.65
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood (2010) 3.57
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med (2004) 3.57
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther (2005) 3.18
Improving T cell therapy for cancer. Annu Rev Immunol (2007) 3.10
An inducible caspase 9 safety switch for T-cell therapy. Blood (2005) 2.93
CARs on track in the clinic. Mol Ther (2011) 2.86
Post-transplant lymphoproliferative disorders. Annu Rev Med (2005) 2.82
The dragon strikes: lessons from the Wenchuan earthquake. Anesth Analg (2010) 2.78
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood (2006) 2.68
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease. Blood (2007) 2.50
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant (2007) 2.33
Men who have sex with men and human immunodeficiency virus/sexually transmitted disease control in China. Sex Transm Dis (2006) 2.18
Adoptive T cell therapy of cancer. Curr Opin Immunol (2010) 2.13
Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood (2013) 2.13
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood (2007) 2.11
Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood (2010) 2.06
Sex-determination gene SRY potentially associates with poor prognosis but not sex bias in hepatocellular carcinoma. Dig Dis Sci (2014) 2.00
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood (2002) 1.98